No abstract

(n¼3), IGA resulted in a negative prenatal growth score in two (67%) cases, with a normal neonatal growth score in all three cases. In the one no IUGR/yes SGA case, IGA did not identify prenatal or neonatal growth pathology. CONCLUSION: We present the first study using IGA to evaluate pathological fetal and neonatal growth in gastroschisis cases. While we found general agreement between IGA and conventional US methods, IGA was able to identify normal growth and pathologic growth restriction missed by conventional methods in the prenatal and neonatal periods.

To characterize information technology (IT) platforms used by maternal-fetal medicine (MFM) practices in the USA. STUDY DESIGN: The Practice Management Division of SMFM administered the Operational Benchmarking Survey to MFM practices recruited by nationwide e-mail and social media solicitation. The online Survey, conducted in the Spring of 2019, comprised >120 questions examining aspects of MFM practice during calendar year 2018. Response data are summarized to provide benchmark information. RESULTS: 45 MFM practices participated, representing 26 USA states and 315 MFM providers. An electronic medical record (EMR) was used by 44 of the practices (98%). Ten different commercial EMRs were used, of which 5 were used by 84% of practices (Figure 1). Interface of the practice EMR to the hospital EHR was reported as Complete or Partial by all Epic users, a majority of Cerner users (3 of 4), and by less than half the users of the other systems. Practices reported that information technology (IT) infrastructure was maintained by a hospital (44%), practice or medical group (28%), contracted external vendor (9%), or a combination of these (18%). IT maintenance expenses were paid by hospital (38%), practice or medical group (55%), or a combination of sources (7%). Telehealth was used for patient evaluation and management visits (E&M) in 33% of practices and teleradiology or remote US reading in 44% (Table). We did not ask for names of commercial systems or platforms used for telemedicine services. Telehealth E&M visits were more common among Corporate-or-Independent practices than among Hospital-based-or-University practices (55% vs 16%, p¼0.04, Chi squared test). CONCLUSION: These data provide a "snapshot" of IT platforms used by a sample of MFM practices. Utilization is generally similar among different types of practice. There is a need for better integration of practice EMRs to hospital EMRs.

No abstract

weeks were included. A receiver operator characteristics (ROC) curve was generated to assess the relationship between A1c and GDM. An ideal cutpoint for early HbA1c was calculated from the ROC curve using the Liu method, and the test characteristics of HbA1c determined. Association of HbA1c above and below the cutpoint with a composite primary outcome of macrosomia (EFW>4000), primary cesarean, shoulder dystocia, pregnancy induced hypertension, hyperbilirubinemia, and hypoglycemia was assessed with a chi squared test. RESULTS: Of 954 women included in the RCT, 501 (52.5%) were included in this analysis. The average GA at HbA1c was 17.5AE1.7, and the average HbA1c at this GA was 5.3AE0.5. The GA at repeat testing was 26.3AE1.4, and 51 women (10.2%) were diagnosed with GDM at 24-28 wks. The ROC curve had an area under the curve (AUC) of 0.63, demonstrating moderate association between early HbA1c and a diagnosis of GDM. At the selected cutoff of 5.4, sensitivity and specificity were both poor (60.8% and 60%, respectively). HbA1c greater than the cutpoint was also not associated with the primary adverse composite outcome (62.6% vs 57.2%, p¼0.23). CONCLUSION: HbA1c for early screening for GDM in obese women performs poorly and should not be used for this purpose.